MATERIALS AND METHODS
Mice. Six weeks old C57BL/6 mice were obtained from the Schizuoka Agricultural Cooperative Association for Laboratory Animals (Hamamatsu) and used at 7-12 weeks of age.
Cultured tumor targets. YAC-1 lymphoma (A./Sn), EL-4 lymphoma (C57BL/6), Meth A fibrosarcoma (BALB/c), K562 myelogeneous leukemia (human) and Daudi lymphoma line (human) were maintained by in vitro passage in RPMI-1640 supplemented with fetal calf serum (10%), L-glutamine (2 mM), 2-mercaptoethanol (5 x 10-5 M), fungizone (0.25 jig/ ml), penicillin (100 U/ml), streptomycin (100jg/ml) and Hepes buffer (20 mM).
Preparation of mouse spleen cells and human peripheral blood lymphocytes. Spleens were aseptically removed, teased apart, and washed in Eagle's minimum essential medium (MEM). After washing, spleen cells were treated with Tris-NH4C1 solution to remove erythrocytes. Following erythrocyte lysis, cells were washed two times with MEM, and cells were resuspendefi in RPMI-1640 culture medium. Human peripheral blood lymphocytes (PBL) were obtained from healthy volunteers by Ficoll-Hypaque method. The number of viable cells was determined by trypan blue exclusion.
In vitro induction of nonspecific killer cells by lectins. Mouse spleen cells (5 x 10') in a volume of 10 ml medium were cultured with Con A (Sigma) in 25 cm2 flasks at 37 C, 5% COZ atomospher. In preliminary experiments, spleen cells after 3-5 days culture showed maximal cytotoxicity to YAC-1 cells. Therefore otherwise stated, spleen cells after 4 days culture were routinely employed as the effector cells. Spleen cells which had been cultured in normal culture medium (without Con A) for 3-5 days showed no cytotoxicity against target tumor cells. Therefore the cytotoxic activity of spleen cells activated with Con A was always compared with that of freshly prepared normal spleen cells. Human PBL were activated in the same manner except Phytohemagglutinin-P (PHA-P, Difco) (10 jig ml) instead of Con A, because the proliferative response of human PBL is stronger with PHA than with Con A.
Reagents. Human IL-2 was obtained from Electro-Nucleoics, INC (Silver Spring, MD.). This IL-2 does not contain lectin or IFN. The dose of IL-2 was expressed as % (v/ v). OK-432 was kindly supplied by Chugai Pharmaceutical Co., Ltd., Tokyo. One KE contains 0.1 mg dried streptococci. Mouse recombinant IFN-y was kindly supplied by Shionogi Pharmaceutical Co., Ltd., Osaka. The titer of IFN-y is determined in terms of IFN-a equivalent.
Cytotoxicity assay. Routinely 1 x 106 effector cells (0.5 ml) was added to 12 x 75 mm plastic tubes (Falcon) containing 1 x 104 51Cr-labeled target cells (0.5 ml). Then Con A (0.5 ml) was added to each tube, and tubes were centrifuged at 500 rpm for 3 min. All samples were incubated for 4 hr at 37 C in a 5% CO atomospher. The culture supernatants (0.8 ml) were harvested with pipets, and were counted in a gamma counter. The percentage of lysis was calculated by the following formula :
The results are shown as mean±s.D. of triplicate. In statistical analysis, Student's t-test was used.
RESULTS

Induction of nonspecific killer cells by Con A
In order to determine the optimal dose of Con A for the induction of nonspecific killer cells, mitogenic response of spleen cells to Con A was firstly examined. The strong mitogenic response was observed at the dose of around 2.5 1a g/ml of Con A (Con A 101u g/ml = 3,660 cpm, 5 ,u g/ml = 75,050 cpm, 2.5 ,u g/ml = 102,330 cpm,1.25 p g/ml = 90,360 cpm, 0.63 p g/ml = 73,260 cpm). Then the effect of the dose of Con A on the induction of nonspecific killer cells was examined using YAC-1, and EL-4 target cells. As shown in Exp I of Table 1 , the highest cytolysis against YAC-1 cells was observed at a dose of 2.51ag/ml of Con A. The optimal dose of Con A for mitogenic response of spleen cells seemed to be almost the same for the induction of nonspecific killer cells. Therefore, 2.5 ,u g/ml of Con A was routinely employed in the following experiments. EL-4 cells were not lysed by Con A activated killer (CAK) cells in a 4 hr-51Cr release assay. When Con A was present during the 4 hr-51Cr release assay (lectin-dependent cytotoxicity assay), EL-4 cells were lysed (Exp II of Table 1 ). A small increase in cytolysis was sometimes observed with unstimulated normal spleen cells in LDCC. Since 5.0 ,u g/ml of Con A was optimal for LDCC, this dose was employed in the following LDCC assay.
Effects of IL-2, OK-432, and IFN-y on the induction of nonspecific killer cells by Con A
The effect of IL-2 on the induction of nonspecific killer cells by Con A was assessed with DCMC and LDCC assays using YAC-1 and EL-4 target cells. As shown in Table 2 , a higher cytolysis was observed with spleen cells treated with Con A plus IL-2 than with those treated with Con A alone. Since the DCMC reactivity against EL-4 cells of spleen cells treated with Con A plus IL-2 was marginal, the spectrum of target cells of the mouse nonspecific killer cells was compared to that of human ones. As shown in Table 3 , human PBL activated with lectin plus IL-2 lysed various types of target cells except Meth A cells. On the other hand, mouse spleen cells activated in the same manner lysed only YAC-1 cells. The effect of OK-432 on the induction of CAK cells was then examined. As shown in Table 4 , a beneficial effect of OK-432 was noticed. The dose effect of OK-432 was not obseraved. As far as we examined, nonspecific killer cells were not induced by OK-432 treatment alone (data not shown). In contrast to IL-2 or OK-432, an enhancing effect by IFN-y was not observed (Table 5) . Finally, the combined effects of IL-2 plus OK-432, or IL-2 plus IFN-y on induction of nonspecific killer cells by Con A were examined. No additive effects were obtained by the above combinations (Table 6 ). 
DISCUSSION
The results presented in this paper have shown that the in vitro induction of nonspecific killer cells by Con A could be augmented by IL-2 or OK-432, but not by IFN-y. In vitro manipulation of effector cells by IL-2 or other biological response modifiers (BRM) seems to be very important for immunotherapy of cancer. IL-2 has been shown to have a variety of immunological activities on T, NK and B cells. Cytotoxic activity as well as the number of spleen cells cultured with Con A plus IL-2 was always greater than that of spleen cells cultured with Con A alone. Furthermore, in vitro maintenance of CAK cells for a couple of weeks could be easily accomplished by IL-2 without loss of activity. In order to check the quality of IL-2 we used, we reexamined some experiments with recombinant human IL-2 (donated by Shionogi Pharmaceutical Co., Ltd.), and almost the same results were obtained. OK-432, a killed preparation of Strepto coccus pyo genes, has been widely used in Japan as a potent biological response modifier and demonstrated to have antitumor activity in both mice and humans (Katano and Torisu 1982; Saito et al. 1984) . OK-432 is known to induce IFN-y in mice (Saito et al. 1980 ). However, IFN-y did not show any enhancing effects on induction of nonspecific killer cells by Con A. Uchida and Micksche (1981) reported that enhancement of NK cell activity by OK-432 was independent of interferon induction. Therefore, other factors rather than IFN may be responsible for the beneficial effect of OK-432.
Although we have not characterized the effector cells yet, both T and non-T cells might be responsible for the nonspecific cytotoxicity recorded in our experiments (Paciucci et al. 1980; Uchida and Yanagawa 1984) . It has been well documented that the main effector cells operating in LDCC are T cells (Asherson et al. 1973; Bevan and Cohn 1975; Bonavida and Bradley 1976; Rubens and Henney 1977) . EL-4 cells were lysed in LDCC. So it could be concluded that T cells are responsible in some parts for the nonspecific cytotoxicity. Mazumder and Rosenberg (1984) reported that adoptive immunotherapy with IL-2 activated cells was successful in the treatment of artificial lung metastases in mice. In the present study, human PBL activated with PHA plus IL-2 lysed various types of tumor cells. Specific or nonspecific killer cells manipulated in vitro with IL-2 or other BRM will become a useful tool for adoptive immunotherapy of cancer.
